insulin-like growth factor-1; mechano growth factor; MGF; somatomedin-C (IGF1, IBP1)
Jump to navigation
Jump to search
Function
- structurally & functionally related to insulin but with a much higher growth-promoting activity
- 85% bound in molecular complex with IGF-binding protein 3 & acid labile subunit glycoprotein.
- may enhance growth of tumors.[3]
- may be a physiological regulator of glucose transport & glycogen synthesis in osteoblasts
Structure
belongs to the insulin family
Compartment
- plasma
- secreted by liver in response to growth hormone Alternate splicing:
- forms IGF-1A & IGF-1B
- named isoforms=4
Expression
- secreted by liver in response to growth hormone
Pathology
- IGF1 deficiency is an autosomal recessive disorder
- low serum IGF-1 levels correlate with increased sarcopenia prevalence & reduced muscle mass in elderly populations.
- low plama IGF-1 levels predicts life expectancy in exceptionally long-lived women & persons of either gender with history of cancer[8]
Pharmacology
- recombinant human IGF-1 (mecasermin)
- FDA-approved for treating growth failure in pediatric patients with severe primary IGF-1 deficiency or growth hormone gene deletion who have developed neutralizing antibodies to growth hormone
- off label uses
- severe insulin resistance syndromes
- - type A insulin resistance, Rabson-Mendenhall syndrome, Donohue's syndrome
- bypasses insulin receptor defects[13]
- growth hormone insensitivity syndrome, including Laron syndrome[12]
- severe insulin resistance syndromes
More general terms
More specific terms
Additional terms
- insulin-like growth factor (IGF)-1 or somatomedin C in serum
- insulin-like growth factor [IGF]-1 receptor (somatomedin-C receptor, CD221, IGF1R)
References
- ↑ Henderson B & Blake S Therapeutic potential of cytokine manipulation TIPS 13:145 1992 PMID: https://pubmed.ncbi.nlm.nih.gov/1589908
- ↑ Solomon DH, in: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
- ↑ 3.0 3.1 LeRoith D IGF-1, Cancer and Aging Aging: Mechanisms and Prevention 34th Annual Meeting of the American Aging Association June 3-6, 2005, Oakland CA
- ↑ UniProt http://www.uniprot.org/uniprot/P05019.html
- ↑ SHMPD; Note: Singapore human mutation andpolymorphism database http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HLA-DQB1
- ↑ NIEHS-SNPs http://egp.gs.washington.edu/data/igf1/
- ↑ Wikipedia; Note: insulin-like growth factor 1 entry http://en.wikipedia.org/wiki/insulin-like_growth_factor_1
- ↑ 8.0 8.1 Milman S, Atzmon G, Huffman DM et al Low insulin-like growth factor-1 level predicts survival in humans with exceptional longevity. Aging Cell. 2014 Aug;13(4):769-71. PMID: https://pubmed.ncbi.nlm.nih.gov/24618355 Free PMC Articl
- ↑ Ferrari U, Schmidmaier R, Jung T et al IGF-I/IGFBP3/ALS Deficiency in Sarcopenia: Low GHBP Suggests GH Resistance in a Subgroup of Geriatric Patients. J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1698-e1707. PMID: https://pubmed.ncbi.nlm.nih.gov/33378445
- ↑ Jiang JJ, Chen SM, Chen J, Wu L, Ye JT, Zhang Q. Serum IGF-1 levels are associated with sarcopenia in elderly men but not in elderly women. Aging Clin Exp Res. 2022 Oct;34(10):2465-2471. PMID: https://pubmed.ncbi.nlm.nih.gov/35962897
- ↑ Bian A, Ma Y, Zhou X, Guo Y, Wang W, Zhang Y, Wang X. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet Disord. 2020 Apr 7;21(1):214. PMID: https://pubmed.ncbi.nlm.nih.gov/32264885 PMCID: PMC7140321 Free PMC article. https://pmc.ncbi.nlm.nih.gov/articles/PMC7140321/
- ↑ 12.0 12.1 Ranke MB. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance. Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7. PMID: https://pubmed.ncbi.nlm.nih.gov/15860416 Review.
- ↑ 13.0 13.1 McDonald A, Williams RM, Regan FM, Semple RK, Dunger DB. IGF-I treatment of insulin resistance. Eur J Endocrinol. 2007 Aug;157 Suppl 1:S51-6. PMID: https://pubmed.ncbi.nlm.nih.gov/17785698 Review.